The global incretin-based drugs market is anticipated to grow at a considerable CAGR of 5.5% during the forecast period. Increased research activity, government initiatives to promote disease awareness, and research grants are primary factors which are expected to fuel the global incretin-based drug market’s growth over the forecast period. Furthermore, rising government spending in R&D activities, as well as new product releases by numerous prominent companies, are expected to further propel the diabetes medicines market.
For instance, in October 2021, Glenmark launched drug in combination of various incretin based drug types including remogliflozin, vildagliptin, metformin fixed-dose combination (FDC) at an affordable cost for adults with type-2 diabetes. Among others, India is the first country to get access to this FDC drug. Glenmark had received an approval for the drug from the Drug Controller General of India (DCGI) for manufacturing and marketing back in September 2021. The new drug launched combines two or more active incretin based drugs in a single dosage form and can manage most of the pathophysiology in managing uncontrolled type-2 Diabetes. Further, in April 2019, Glenmark developed Remogliflozin, an oral anti-diabetic medicine that is deemed helpful in treating individuals with type-2 diabetes mellitus. Thus, increased product development in emerging countries along with rising healthcare expenditure will bolster the growth of the market.
To Request a Sample of our Report on Incretin Based Drugs Market: https://www.omrglobal.com/request-sample/incretin-based-drugs-market
Market Coverage
- The market number available for – 2021-2029
- Base year- 2021
- Forecast period- 2023-2029
Segment Covered-
- By Drug Type
- By Route of Administration
- By Distribution Channel
Regions Covered-
- North America
- Europe
- Asia-Pacific
Rest of the World
Competitive Landscape- including AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Co., GlaxoSmithKline plc., Merck & Co., and others.
Incretin Based Drugs Market Report Segment
By Drug Type
- Glucagon-like Peptide-1 Receptor Agonists
- Dipeptidyl Peptidase-4 Inhibitor
By Route of Administration
- Oral
- Injectable
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
A full Report of Incretin Based Drugs Market is Available @ https://www.omrglobal.com/industry-reports/incretin-based-drugs-market
Incretin Based Drugs Market Report Segment by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
- Latin America
- Middle East & Africa
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
